Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review
- PMID: 29226101
- PMCID: PMC5719192
- DOI: 10.14218/JCTH.2017.00021
Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review
Abstract
Hepatitis C (HCV) infection has an estimated global prevalence of 2.5%, causing chronic liver disease in 170 million people worldwide. Recent data has identified HCV infection as a risk factor for subclinical and clinical cardiovascular disease (CVD), but these data have been mixed and whether HCV is an independent risk factor for development of CVD remains controversial. In this review, we present the literature regarding the association of HCV with subclinical and clinical CVD and the possible underlying mechanisms leading to increased CVD among those infected with HCV. HCV infection leads to increased CVD via direct and indirect mechanisms with chronic inflammation, endothelial dysfunction and direct invasion of the arterial wall cited as possible mechanisms. Our review showed that HCV infection, particularly chronic HCV infection, appears to lead to increased subclinical CVD most consistently and potentially also to increased clinical CVD outcomes, leading to increased morbidity and mortality. Furthermore, the majority of studies evaluating the impact of HCV therapy on CVD morbidity and mortality showed an improvement in subclinical and clinical CVD endpoints in patients who were successfully treated and achieved sustained viral suppression. These results are of particular interest following the development of new direct antiviral agents which have made HCV eradication simple and feasible for many more patients globally, and in doing so may possibly reduce CVD morbidity and mortality in those with chronic HCV infection.
Keywords: Atherosclerosis; Cardiovascular disease; Cerebrovascular disease; Coronary heart disease; Hepatitis C.
Conflict of interest statement
The authors have no conflict of interests related to this publication.
Figures


Similar articles
-
Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.Gastroenterology. 2019 Mar;156(4):987-996.e8. doi: 10.1053/j.gastro.2018.11.022. Epub 2018 Nov 13. Gastroenterology. 2019. PMID: 30445009
-
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update.Front Pharmacol. 2021 May 11;12:678546. doi: 10.3389/fphar.2021.678546. eCollection 2021. Front Pharmacol. 2021. PMID: 34045969 Free PMC article. Review.
-
Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2. J Hepatol. 2018. PMID: 29505844
-
Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review.Clin Cardiol. 2020 Mar;43(3):222-234. doi: 10.1002/clc.23299. Epub 2019 Nov 30. Clin Cardiol. 2020. PMID: 31785111 Free PMC article. Review.
-
A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study.J Infect Dis. 2016 Jan 15;213(2):257-65. doi: 10.1093/infdis/jiv396. Epub 2015 Jul 27. J Infect Dis. 2016. PMID: 26216904 Free PMC article.
Cited by
-
Hepatitis C virus antibody seropositivity is associated with albuminuria but not peripheral artery disease in patients with type 2 diabetes.Sci Rep. 2024 Feb 26;14(1):4607. doi: 10.1038/s41598-024-55352-7. Sci Rep. 2024. PMID: 38409227 Free PMC article.
-
Risk of New-Onset Atrial Fibrillation Among Asian Chronic Hepatitis C Virus Carriers: A Nationwide Population-Based Cohort Study.J Am Heart Assoc. 2019 Nov 19;8(22):e012914. doi: 10.1161/JAHA.119.012914. Epub 2019 Nov 12. J Am Heart Assoc. 2019. PMID: 31711382 Free PMC article.
-
Advanced detection strategies for cardiotropic virus infection in a cohort study of heart failure patients.Lab Invest. 2022 Jan;102(1):14-24. doi: 10.1038/s41374-021-00669-4. Epub 2021 Oct 4. Lab Invest. 2022. PMID: 34608239 Free PMC article.
-
Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States.Am J Prev Cardiol. 2023 Nov 12;16:100604. doi: 10.1016/j.ajpc.2023.100604. eCollection 2023 Dec. Am J Prev Cardiol. 2023. PMID: 38162437 Free PMC article.
-
Association Between Endophthalmitis and the Incidence of Acute Coronary Syndrome in Patients With Ankylosing Spondylitis: A Nationwide, Population-Based Cohort Study.Front Immunol. 2022 Mar 25;13:843796. doi: 10.3389/fimmu.2022.843796. eCollection 2022. Front Immunol. 2022. PMID: 35401539 Free PMC article.
References
-
- Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat. 2013;20:600–601. 10.1111/jvh.12123. - DOI - PubMed
-
- Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22:7824–7840. 10.3748/wjg.v22.i34.7824. - DOI - PMC - PubMed
-
- Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52. 10.7150/ijms.3.47. - DOI - PMC - PubMed
-
- Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–S173. 10.1016/j.dld.2014.10.005. - DOI - PubMed
-
- White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–844. 10.1016/j.jhep.2008.08.006. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources